DNA Form 4: Director Disposes of 20,000 Class A Shares at ~$11

Rhea-AI Filing Summary

Ginkgo Bioworks director Henry Christian O reported two open-market sales totaling 20,000 shares of Class A common stock. The Form 4 shows a sale of 10,000 shares on 09/08/2025 at a weighted-average price of $10.92 and a sale of 10,000 shares on 09/09/2025 at a weighted-average price of $11.06. After the first sale the filing lists 34,310 shares beneficially owned and after the second sale 24,310 shares beneficially owned, both held directly. The filing includes explanations that the reported prices are weighted averages of multiple transactions within the stated price ranges.

Positive

• Transparent disclosure: The Form 4 reports the sales with weighted-average prices and offers to provide transaction-level breakouts on request.
• Clear ownership reporting: The filing specifies direct beneficial ownership amounts before and after the reported transactions.

Negative

• Insider selling: The reporting person disposed of 20,000 Class A shares, reducing direct holdings to 24,310 shares.
• No context provided for sales: The Form 4 does not state the reason for the disposals or any planned future transactions.

Insights

Corporate Governance Expert

TL;DR: Director executed routine open-market sales reducing direct holdings by 20,000 shares; disclosure appears complete.

The Form 4 documents that Henry Christian O, identified as a director, sold a total of 20,000 Class A shares in two transactions on consecutive dates at weighted-average prices of $10.92 and $11.06. The filing states the resulting direct beneficial ownership levels after each sale. The inclusion of weighted-average price ranges and an explicit undertaking to provide breakouts on request indicates attention to disclosure detail. This is a standard Section 16 reporting event; the filing does not disclose any non-routine governance actions or changes in board status.

Securities Analyst

TL;DR: Insider sales reduced share count materially for an individual but show no additional transactional context or derivative activity.

The reported disposals are limited to non-derivative Class A common stock sales totaling 20,000 shares across two dates with weighted-average prices provided and specified trading ranges. The filing lists direct ownership falling from 34,310 to 24,310 shares following the second reported sale. There are no derivative transactions or acquisitions reported on this Form 4, and no amendments or irregularities noted in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENRY CHRISTIAN O

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/08/2025		S		10,000	D	$10.92(1)	34,310	D
Class A Common Stock	09/09/2025		S		10,000	D	$11.06(2)	24,310	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.91 to $11.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.97 to $11.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Karen Tepichin, Attorney-in-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Henry Christian O report for Ginkgo Bioworks (DNA)?

The Form 4 reports two open-market sales: 10,000 shares on 09/08/2025 at a weighted-average $10.92 and 10,000 shares on 09/09/2025 at a weighted-average $11.06.

How many shares does Henry Christian O beneficially own after the reported sales?

The filing lists beneficial ownership of 34,310 shares after the first sale and 24,310 shares after the second sale, held directly.

Were any derivative securities reported on this Form 4 for DNA?

No. Table II for derivative securities in the provided content contains no reported acquisitions or dispositions.

Do the reported prices reflect single trades or ranges?

The filing states the reported prices are weighted averages of multiple transactions, with price ranges of $10.91–$11.02 and $10.97–$11.24 respectively.

Who signed or submitted the Form 4 on behalf of the reporting person?

The signature block in the content shows the form was signed by Karen Tepichin, Attorney-in-Fact.